Global High Potency API CDMOs Market: Innovations in Manufacturing Technology Fueling Growth by 2027
The Global High Potency API CDMOs Market is expected to witness a high and a single-digit growth by 2027. The principal factors fueling the market’s growth are growing demand for oncology medications, ...
Outsource API manufacturing to India for lower costs, GMP-compliant quality, scalable production, and faster time-to-market for pharma companies.
Pharmaceutical Technology on MSN
AbbVie announces $380m investment in North Chicago API facilities
Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.
(MENAFN- IMARC Group) An API (Active Pharmaceutical Ingredient) is the biologically active component of a drug that produces the intended therapeutic effect. It is the essential substance in medicines ...
The National Drug Policy, 1982 marked a revolutionary shift in Bangladesh's pharmaceutical industry. Following its adoption, domestic production surged, local companies gained market dominance, and ...
Eli Lilly and Company has announced plans to invest $6.5bn in an active pharmaceutical ingredients (API) manufacturing facility at Generation Park in Houston, in the US state of Texas. The new ...
Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "Veterinary Active Pharmaceutical Ingredients Manufacturing - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering ...
(MENAFN- IMARC Group) Setting up an API Manufacturing facility necessitates a detailed market analysis alongside granular insights into various operational aspects, including unit processes, raw ...
Poor API quality may often lead to delays in production and a shortage of supply. The API is, one might say, the most important element in a pharmaceutical product. Poor-quality APIs that do not meet ...
MHRA approves Loba Biotech to manufacture Pegasys API, enabling pharma& to strengthen UK supply and ensure continued access for eligible patients. Following the MHRA decision, pharma& expects that ...
The project, approved in 2008, was meant to anchor the industry’s next phase of growth. Nearly two decades later, the site remains largely idle. On a quiet December 11 afternoon, entering the API ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results